According to Dr. Brunsting, "TMR is shown to provide significant and enduring patient benefits and is an important tool for treating advanced cases and optimizing outcomes in these increasingly complex revascularization cases. Cardiogenesis is advancing the TMR therapy with innovative new tools building on the foundation of their flexible fiberoptic delivery system, enabling delivery through small ports in a closed-chest, robotically assisted technique. Our goal in implementing robotically assisted TMR is to provide well documented patient benefits with significantly reduced procedural morbidity and related hospitalization."
"We are fortunate to be associated with Dr. Brunsting, a leading innovator in cardiothoracic surgery, as well as the highly skilled team and first-class facilities at Centennial", stated Michael J. Quinn, Cardiogenesis chairman and CEO. "We are impressed with his accomplishments in implementing robotically-assisted cardiac techniques to improve the patient experience, and are grateful to have his leadership and direct involvement in the implementation of our advanced TMR PLUS robotically assisted technique."
Dr. Brunsting has significant experience in this type of surgery, having performed more than 130 robotically-assisted, endoscopic cardiothoracic procedures. He also has conducted many open TMR surgeries using the Cardiogenesis system. With his partner, Dr. Robert S. Binford, M.D., Dr. Brunsting has also trained other physicians from the United States, Japan and Australia on the Intuitive Surgical da Vinci robotic system. Dr. Brunsting has been utilizing TMR for the treatment of patients debilitated by angina due to late stage coronary artery disease since 1999.
Dr. Brunsting is the principal investigator in a small, FDA-mandated study to demonstrate the safety and feasibility of closed chest, robotically-assisted TMR at multiple centres. Cardiogenesis is now enrolling and training centres with robotic experience to participate in the study. Centennial was the first medical centre in Tennessee to perform robotic cardiac bypass surgery and has developed one of the leading cardiac robotic programmes in the country.
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is specialized in devices that stimulate cardiac angiogenesis. The company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina.
Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the United States and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.